Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that Restylane® could serve as a repair matrix which also
maintains IL triamcinolone acetonide concentrations at higher levels for a longer period of
time in the skin, giving a more sustained local anti-inflammatory effect and thus, arresting
the AA process and promoting hair regrowth. Furthermore, the combination of Restylane® with
IL triamcinolone acetonide injections may prevent a common side effect, atrophy. With the
prevention of scalp atrophy and the preservation of higher concentrations of triamcinolone
acetonide for longer periods of time, patients may see a better clinical response for a
longer period of time. Quality of life may improve as the number of clinic visits decreases
as would the number of IL corticosteroid injections.
Phase:
Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute